Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
1	hours por rosponso:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Horton Kenneth L (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					$ \mathbf{V} $	VERTEX PHARMACEUTICALS INC / MA [VRTX]									ationship of Reportin c all applicable) Director Officer (give title below)		10% Ow Other (s below)		ner	
						3. Date of Earliest Transaction (Month/Day/Year) 02/05/2014									EVP & Chief Leg			al Officer		
50 NORTHERN AVENUE					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) BOSTON MA 02210													X	,						
(City) (State) (Zip)																				
		Tab	le I - Noi	n-Deri	vativ	e Se	curities	s Ac	quired,	Dis	posed o	f, or Be	neficia	lly (Owned					
Date				Date	Transaction ate Ionth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			4 and Securit		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) o	Price		Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock 02/05/					5/201	/2014		A		17,250	250 ⁽¹⁾ A		01	33,874			D			
Common Stock														366			I	401(k)		
		-	Table II -								osed of, onvertil			y Oı	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	Code (Inst		n of		6. Date Exercisable a Expiration Date (Month/Day/Year)		!	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se	B. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares							
Employee Stock Option (right to	\$77.31	02/05/2014			A		51,000		(2)	O	02/04/2024	Common Stock	51,000		\$0.00	51,000)	D		

Explanation of Responses:

1. Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products.

2. The option vests in 16 quarterly installments from 02/05/2014.

Remarks:

Kenneth L. Horton

** Signature of Reporting Person

02/07/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.